{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:09:35Z","timestamp":1794535775213,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neubiorev.2025.106086","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T10:59:09Z","timestamp":1740826749000},"page":"106086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"172","author":[{"given":"B.","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kervadec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fauvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Strika-Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Amirouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Bezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Piolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Benyamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2025.106086_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib2","doi-asserted-by":"crossref","DOI":"10.1556\/2054.2024.00354","article-title":"Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives","author":"Aday","year":"2024","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.neubiorev.2025.106086_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib4","first-page":"155","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020"},{"key":"10.1016\/j.neubiorev.2025.106086_bib5","doi-asserted-by":"crossref","unstructured":"Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths\u00a0Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. 2021 May 1;78(5):481-489.","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"10.1016\/j.neubiorev.2025.106086_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2025.106086_bib7","first-page":"1","article-title":"Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States special operations forces Veterans","author":"Armstrong","year":"2023","journal-title":"Mil. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib8","article-title":"Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties","author":"Atiq","year":"2024","journal-title":"Psychopharmacol. (Berl. )."},{"key":"10.1016\/j.neubiorev.2025.106086_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00322","article-title":"The mechanistic divide in psychedelic neuroscience: an unbridgeable gap?","volume":"21","author":"Barksdale","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neubiorev.2025.106086_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/2045125314527985","article-title":"Classical hallucinogens as antidepressants? a review of pharmacodynamics and putative clinical roles","volume":"4","author":"Baumeister","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib12","article-title":"Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","author":"Becker","year":"2022","journal-title":"Int. J. Neuropsychopharmacol. pyac075"},{"key":"10.1016\/j.neubiorev.2025.106086_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib15","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","article-title":"Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study","volume":"14","author":"Breeksema","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2025.106086_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241278873","article-title":"Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response","author":"Calder","year":"2024","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2025.106086_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2025.106086_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neubiorev.2025.106086_bib20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1360-0443.2004.00715.x","article-title":"Addiction and spirituality","volume":"99","author":"Cook","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2025.106086_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s44184-024-00091-w","article-title":"Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome","volume":"3","author":"Dahan","year":"2024","journal-title":"Npj Ment. Health Res."},{"key":"10.1016\/j.neubiorev.2025.106086_bib24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00213-022-06063-2","article-title":"Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil","volume":"239","author":"Daldegan-Bueno","year":"2022","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2025.106086_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","article-title":"5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety","volume":"45","author":"Davis","year":"2019","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.neubiorev.2025.106086_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neubiorev.2025.106086_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"De Vos","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/cells12060963","article-title":"Psychedelic targeting of metabotropic glutamate receptor 2 and its implications for the treatment of alcoholism","volume":"12","author":"Domanegg","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neubiorev.2025.106086_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221085800","article-title":"Integration in psychedelic-assisted treatments: recurring themes in current providers\u2019 definitions, challenges, and concerns","author":"Earleywine","year":"2022","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression \u2013 A first-in-kind open-label pilot study","volume":"369","author":"Ellis","year":"2025","journal-title":"J. Affect. Disord"},{"key":"10.1016\/j.neubiorev.2025.106086_bib31","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey","author":"Garcia-Romeu","year":"2020","journal-title":"Front. Psychiatry 10, 955"},{"key":"10.1016\/j.neubiorev.2025.106086_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction","volume":"7","author":"Garcia-Romeu","year":"2015","journal-title":"Curr. Drug Abuse Rev"},{"key":"10.1016\/j.neubiorev.2025.106086_bib34","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2025.106086_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2215-0366(23)00363-2","article-title":"Treatment with psychedelics is psychotherapy: beyond reductionism","volume":"11","author":"Gr\u00fcnder","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2025.106086_bib39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: A history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci. Policy Law"},{"key":"10.1016\/j.neubiorev.2025.106086_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic Acid Diethylamide\u2013Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib44","first-page":"1","article-title":"LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up","author":"Holze","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106086_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy","volume":"74","author":"Horton","year":"2021","journal-title":"Am J Psychother"},{"key":"10.1016\/j.neubiorev.2025.106086_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/02698811231200019","article-title":"Assessment of the acute subjective psychedelic experience: a review of patient-reported outcome measures in clinical research on classical psychedelics","volume":"38","author":"Hovmand","year":"2024","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib48","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.535","article-title":"Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial","volume":"9","author":"Husain","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.neubiorev.2025.106086_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neubiorev.2025.106086_bib50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol. (Oxf. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2025.106086_bib53","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00213-020-05703-9","article-title":"Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs","volume":"237","author":"Kangaslampi","year":"2020","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2025.106086_bib54","article-title":"Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey","author":"Kervadec","year":"2023","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of Addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106086_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022799","article-title":"Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development","volume":"6","author":"Lambe","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neubiorev.2025.106086_bib58","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","article-title":"LSD-induced entropic brain activity predicts subsequent personality change: LSD-induced entropic brain activity","volume":"37","author":"Lebedev","year":"2016","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neubiorev.2025.106086_bib59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","article-title":"Randomized trial of ketamine masked by surgical anesthesia in patients with depression","volume":"1","author":"Lii","year":"2023","journal-title":"Nat. Ment. Health"},{"key":"10.1016\/j.neubiorev.2025.106086_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111129","article-title":"Classic psychedelics and the treatment for alcoholism","volume":"135","author":"Lodetti","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib61","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neubiorev.2025.106086_bib62","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106086_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nn.2723","article-title":"From reinforcement learning models to psychiatric and neurological disorders","volume":"14","author":"Maia","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1025726","article-title":"The economics of psychedelic-assisted therapies: A research agenda","volume":"13","author":"Marseille","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib65","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.neubiorev.2025.106086_bib66","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib67","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.573953","article-title":"Treatment of a complex personality disorder using repeated doses of LSD\u2014a case report on significant improvements in the absence of acute drug effects","volume":"11","author":"M\u00fcller","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41386-022-01424-z","article-title":"Does the trip matter? investigating the role of the subjective effects of psychedelics in persisting therapeutic effects","volume":"48","author":"Nautiyal","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106086_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/35053570","article-title":"Molecular basis of long-term plasticity underlying addiction","volume":"2","author":"Nestler","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0166-4328(02)00311-X","article-title":"Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety","volume":"140","author":"Nic Dhonnchadha","year":"2003","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2025.106086_bib73","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/02698811221101061","article-title":"Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample","volume":"36","author":"Nygart","year":"2022","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib76","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neubiorev.2025.106086_bib77","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41587-024-02285-1","article-title":"Next-generation psychedelics: should new agents skip the trip?","volume":"42","author":"Peplow","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib78","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1017\/S0033291719002393","article-title":"LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making","volume":"50","author":"Pokorny","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neubiorev.2025.106086_bib79","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.neubiorev.2025.106086_bib80","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1523\/JNEUROSCI.1939-17.2018","article-title":"Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study","volume":"38","author":"Preller","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib81","first-page":"221","article-title":"Phenomenology, structure, and dynamic of psychedelic states","author":"Preller","year":"2018","journal-title":"Behav. Neurobiol. Psychedelic Drugs"},{"key":"10.1016\/j.neubiorev.2025.106086_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106086_bib83","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neubiorev.2025.106086_bib84","doi-asserted-by":"crossref","unstructured":"Robin L Carhart-Harris , Mark Bolstridge , James Rucker , Camilla M J Day , David Erritzoe , Mendel Kaelen , Michael Bloomfield 4, James A Rickard 5, Ben Forbes 6, Amanda Feilding , David Taylor , Steve Pilling , Valerie H Curran , David J Nutt , Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study, Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016\/S2215-0366(16)30065-7.","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"10.1016\/j.neubiorev.2025.106086_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2023.2227171","article-title":"Impact of a naturalistic psychedelic experience on smoking: a retrospective survey","author":"Romeo","year":"2023","journal-title":"J. Psychoact. Drugs 1\u201310."},{"key":"10.1016\/j.neubiorev.2025.106086_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review","volume":"137","author":"Romeo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neubiorev.2025.106086_bib87","first-page":"1","article-title":"Significant psychedelic experiences evaluated for mystical characteristics associated with cannabis use reduction and psychological flexibility improvement: a naturalistic cross-sectional retrospective survey","author":"Romeo","year":"2024","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2025.106086_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115880","article-title":"Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review","volume":"335","author":"Romeo","year":"2024","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neubiorev.2025.106086_bib89","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.22181","article-title":"Interrupting the psychedelic experience through contextual manipulation to study experience efficacy","volume":"7","author":"Roseman","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neubiorev.2025.106086_bib90","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib91","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.20220835","article-title":"Antidepressant effects of psilocybin in the absence of psychedelic effects","volume":"180","author":"Rosenblat","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib92","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.neubiorev.2025.106086_bib93","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neubiorev.2025.106086_bib94","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neubiorev.2025.106086_bib95","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient\u2010informed low\u2010dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.neubiorev.2025.106086_bib96","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neubiorev.2025.106086_bib97","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","article-title":"Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder","volume":"26","author":"Spriggs","year":"2021","journal-title":"Eat. Weight Disord. - Stud. Anorex. Bulim. Obes"},{"key":"10.1016\/j.neubiorev.2025.106086_bib98","article-title":"Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey","author":"Stroud","year":"2024","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2025.106086_bib99","article-title":"Therapeutic frameworks in integration sessions in substance-assisted psychotherapy: a systematised review","author":"Thal","year":"2023","journal-title":"Clin. Psychol. Psychother. cpp. 2945"},{"key":"10.1016\/j.neubiorev.2025.106086_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"Van Elk","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib101","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00213-021-06046-9","article-title":"Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study","volume":"239","author":"Van Oorsouw","year":"2022","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2025.106086_bib102","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41398-024-03074-9","article-title":"Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants","volume":"14","author":"Vizeli","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib103","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106086_bib104","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.neubiorev.2025.106086_bib105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/wps.20238","article-title":"How important are the common factors in psychotherapy? An update","volume":"14","author":"Wampold","year":"2015","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106086_bib106","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance","volume":"11","author":"Wolff","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106086_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241249698","article-title":"Measuring psychotherapeutic processes in the context of psychedelic experiences: validation of the general change mechanisms questionnaire (GCMQ)","author":"Wolff","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106086_bib109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/02698811211073758","article-title":"The Acceptance\/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs\u2019 effects on psychological flexibility","volume":"36","author":"Wolff","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s44159-024-00345-6","article-title":"Clinically relevant acute subjective effects of psychedelics beyond mystical experience","volume":"3","author":"Yaden","year":"2024","journal-title":"Nat. Rev. Psychol."},{"key":"10.1016\/j.neubiorev.2025.106086_bib111","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The Subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425000867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425000867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:29:36Z","timestamp":1777642176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763425000867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":111,"alternative-id":["S0149763425000867"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106086","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106086"}}